Condition 1: Multiple Sclerosis. Condition 2: Gastrointestinal problems. Multiple sclerosis Disease of digestive system, unspecified
Conditions
Interventions
Intervention 1: Intervention group: Capsule Omeprazole 20 mg (Sobhan company) once daily. Intervention 2: Control group: Capsule placebo once daily.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with recurrent types of MS between 18 and 65 years and hospitalized Receive 1 gram of corticosteroid pulse daily for at least 3 days Patient consent to participate in the study
Exclusion criteria
Exclusion criteria: Presence or history of peptic ulcer disease or gastroesophageal reflux disease or inflammatory bowel disease such as colitis and Crohn's disease Simultaneous administration of other drugs that cause damage to the gastrointestinal mucosa and increase the risk of ulcers and bleeding, such as oral corticosteroids, NSAIDs, anticoagulants, antiplatelets, etc Receive acid-suppressing drugs such as PPIs and H2R antagonists in the last week Acute or chronic renal and hepatic failure clcr<30 , child-pughscore<2 Pregnancy and lactation Patients receiving IVIG or plasma exchange at the same time, other than a corticosteroid pulse.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dyspepsia symptoms (including abdominal pain, nausea, heartburn, vomiting). Timepoint: Baseline, at the time of discharge from the hospital, 2 weeks after the discharge. Method of measurement: Direct questioning of the patient and, if necessary, clinical examination.;The dose of Famotidine as PRN for dyspepsia management. Timepoint: At the time of discharge from the hospital, 2 weeks after the discharge. Method of measurement: Direct observing the patient medical report regarding the dose of drug receiving.;Defecation changes. Timepoint: Baseline, at the time of discharge from the hospital, 2 weeks after the discharge. Method of measurement: Direct questioning of the patient and, if necessary, clinical examination. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of receiving corticosteroid pulse. Timepoint: At the time of discharge from the hospital. Method of measurement: Patient medical report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMina Hejazi
Tehran University of Medical Sciences
Outcome results
None listed